ABSTRACT
We synthesize optically active (R)-terbutaline 2, which is an anti-asthmatic drug, through recyclable catalytic asymmetric transfer hydrogenation (RCATH). Various chloroketones 4 were prepared and RCATH was performed on them. The products exhibit moderate to high enantioselectivity. In particular, the hydrogenation of acyl substituted substrates 4c yields chiral secondary alcohols 5c in good yield and enantioselectivity. Furthermore, (R)-terbutaline 2 can be synthesized in one step from the resulting secondary alcohol 5 without racemization.
Subject(s)
Anti-Asthmatic Agents/chemical synthesis , Green Chemistry Technology , Ionic Liquids/chemistry , Terbutaline/chemical synthesis , Anti-Asthmatic Agents/chemistry , Catalysis , Hydrogenation , Molecular Structure , Stereoisomerism , Terbutaline/chemistryABSTRACT
An increase activity of butyrylcholinesterase is believed to contribute to Alzheimer's disease. Bambuterol is a known potent inhibitor of butyrylcholinesterase, but it has undesired cardiac effects and less lipophilicity. Thirteen bambuterol analogues were synthesized using 1-(3, 5-dihydroxyphenyl) ethanone as a starting material. In-vitro cholinesterase assay established that the majority of the compounds are specific butyrylcholinesterase inhibitors. Out of the 13 compounds, two bambuterol derivatives, BD-6 and BD-11 exhibited similar efficacies in inhibiting butyrylcholinesterase with fewer effects on heart and enhanced possibilities of permeating through the blood-brain barrier as compared to bambuterol. These bambuterol analogues may provide better alternatives for treatments of Alzheimer's disease.
Subject(s)
Butyrylcholinesterase/metabolism , Cholinesterase Inhibitors/chemical synthesis , Cholinesterase Inhibitors/pharmacology , Drug Design , Terbutaline/analogs & derivatives , Acetylcholinesterase/metabolism , Adult , Animals , Chemistry Techniques, Synthetic , Cholinesterase Inhibitors/adverse effects , Cholinesterase Inhibitors/chemistry , Computer Simulation , Heart Rate/drug effects , Humans , Male , Mice , Terbutaline/adverse effects , Terbutaline/chemical synthesis , Terbutaline/chemistry , Terbutaline/pharmacologyABSTRACT
Three stable and simple synthetic routes of labeled D9 -Mabuterol, D9 -Bambuterol, and D9 -Cimbuterol were described with 98.5%, 99.7%, and 98.4% isotopic abundance and good purity. These structures and isotope-abundance were confirmed according to 1 H NMR and liquid chromatography-tandem mass spectrometry.
Subject(s)
2-Hydroxyphenethylamine/analogs & derivatives , Aniline Compounds/chemistry , Aniline Compounds/chemical synthesis , Clenbuterol/analogs & derivatives , Deuterium/chemistry , Terbutaline/analogs & derivatives , 2-Hydroxyphenethylamine/chemical synthesis , 2-Hydroxyphenethylamine/chemistry , Chemistry Techniques, Synthetic , Clenbuterol/chemical synthesis , Clenbuterol/chemistry , Isotope Labeling , Terbutaline/chemical synthesis , Terbutaline/chemistryABSTRACT
The objective of this study was to prepare and evaluate terbutaline sulphate (TBS) bi-layer tablets for once-daily administration. The bi-layer tablets consisted of an immediate-release layer and a sustained-release layer containing 5 and 10 mg TBS, respectively. The sustained-release layer was developed by using Compritol®888 ATO, Precirol® ATO 5, stearic acid, and tristearin, separately, as slowly eroding lipid matrices. A full 4 × 2(2) factorial design was employed for optimization of the sustained-release layer and to explore the effect of lipid type (X 1), drug-lipid ratio (X 2), and filler type (X 3) on the percentage drug released at 8, 12, and 24 h (Y 1, Y 2, and Y 3) as dependent variables. Sixteen TBS sustained-release matrices (F1-F16) were prepared by melt solid dispersion method. None of the prepared matrices achieved the targeted release profile. However, F2 that showed a relatively promising drug release was subjected to trial and error optimization for the filler composition to develop two optimized matrices (F17 and F18). F18 which consisted of drug-Compritol®888 ATO at ratio (1:6 w/w) and Avicel PH 101/dibasic calcium phosphate mixture of 2:1 (w/w) was selected as sustained-release layer. TBS bi-layer tablets were evaluated for their physical properties, in vitro drug release, effect of storage on drug content, and in vivo performance in rabbits. The bi-layer tablets showed acceptable physical properties and release characteristics. In vivo absorption in rabbits revealed initial high TBS plasma levels followed by sustained levels over 24 h compared to immediate-release tablets.
Subject(s)
Lipids/chemical synthesis , Lipids/pharmacokinetics , Terbutaline/chemical synthesis , Terbutaline/pharmacokinetics , Administration, Oral , Animals , Bronchodilator Agents/administration & dosage , Bronchodilator Agents/chemical synthesis , Bronchodilator Agents/pharmacokinetics , Chemistry, Pharmaceutical , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/chemical synthesis , Delayed-Action Preparations/pharmacokinetics , Drug Administration Schedule , Drug Evaluation, Preclinical/methods , Female , Lipids/administration & dosage , Male , Rabbits , Tablets, Enteric-Coated , Terbutaline/administration & dosageABSTRACT
The present article describes the asymmetric synthesis of (R)-bambuterol hydrochloride based on 1-(3,5-dihydroxyphenyl)ethanone as starting material, which was esterified by dimethylcarbamic chloride, and brominated by copper (II) bromide. Then the carbonyl group was reduced efficiently using (-)-B-chlorodiisopinocamphenylborane [(-)-DIP-chloridetrade mark] as an asymmetrical reducing agent. Followed by epoxide ring closure with NaOH and ring expansion with tert-butylamine led to the desired product (R)-bambuterol with e.e. up to 99%. The optical properties and absolute configuration of (R)-bambuterol hydrochloride were further investigated using circular dichroism spectroscopy and X-ray single crystal analysis.